Table 1.
Baseline demographics for the cross-sectional MS participants whose data were used in computing correlations.
| Demographics | Cross-sectional MS (N = 93)a | ||
|---|---|---|---|
| PPMS (n = 38) | SPMS (n = 19) | RRMS (n = 35) | |
| Age—year | |||
| Mean ± SD | 58.8 ± 7.8 | 60.0 ± 8.2 | 50.0 ± 10.2 |
| Median | 58.8 | 60.7 | 49.5 |
| Range | 28.2–70.8 | 41.9–71.9 | 30.2–77.2 |
| Gender—no. of patients (%) | |||
| Female | 52.6 | 57.9 | 54.3 |
| Male | 47.3 | 42.1 | 45.7 |
| Other clinical characteristics | |||
| Disease duration—year | |||
| Mean ± SD | 15.7 ± 8.3 | 26.8 ± 11.2 | 12.4 ± 10.1 |
| Median | 14.6 | 29.4 | 9.0 |
| Range | 4.2–44.2 | 5.0–48.9 | 1.1–43.4 |
| NeurExb | |||
| Mean ± SD | 94.0 ± 61.8 | 119.0 ± 68.9 | 35.1 ± 35.6 |
| Median | 79.9 | 102.4 | 24.2 |
| Range | 10.7–308.4 | 24.4–263.1 | 2.5–171.7 |
| EDSSb | |||
| Mean ± SD | 5.7 ± 1.3 | 6.0 ± 1.1 | 3.3 ± 1.6 |
| Median | 6.0 | 6.5 | 3.0 |
| Range | 2.5–8.0 | 3.5–7.5 | 1.0–6.5 |
| SNRSb | |||
| Mean ± SD | 56.5 ± 11.2 | 54.1 ± 10.2 | 74.4 ± 12.3 |
| Median | 59.0 | 54.0 | 74.0 |
| Range | 29.0–85.0 | 39.0–74.0 | 41.0–98.0 |
| CombiWISEb | |||
| Mean ± SD | 48.1 ± 13.4 | 50.5 ± 12.1 | 27.1 ± 11.5 |
| Median | 46.6 | 53.6 | 26.0 |
| Range | 18.6–80.6 | 27.7–73.8 | 8.4–55.9 |
| SDMTb | |||
| Mean ± SD | 39.7 ± 11.9 | 39.5 ± 12.3 | 49.5 ± 14.7 |
| Median | 42.0 | 42.0 | 49.0 |
| Range | 17.0–61.0 | 9.0–60.0 | 23.0–84.0 |
| MSFCb | |||
| Mean ± SD | −1.2 ± 2.2 | −0.9 ± 1.6 | 0.2 ± 0.6 |
| Median | −0.2 | −0.5 | 0.3 |
| Range | −6.8–0.9 | −0.63–0.9 | −1.1–1.0 |
| 9HPTb | |||
| Mean ± SD | 49.1 ± 59.0 | 44.4 ± 44.3 | 22.9 ± 6.4 |
| Median | 26.8 | 26.7 | 21.6 |
| Range | 18.6–274.2 | 18.2–166.2 | 15.8–52.2 |
| 25FWb | |||
| Mean ± SD | 38.7 ± 59.5 | 30.4 ± 40.9 | 5.7 ± 2.7 |
| Median | 8.5 | 15.1 | 4.8 |
| Range | 4.0–179.9 | 3.7–179.9 | 3.6–15.6 |
| PASATb | |||
| Mean ± SD | 44.5 ± 13.7 | 47.7 ± 12.4 | 46.7 ± 12.3 |
| Median | 48.5 | 51.0 | 50.0 |
| Range | 6.0–60.0 | 14.0–60.0 | 22.0–60.0 |
Patients were split by MS disease subtype into primary progressive MS (PPMS), secondary progressive MS (SPMS), and relapsing remitting MS (RRMS). Data are represented as sample size (%) or mean ± standard deviation, median and range. Percentages do not always sum to 100 due to rounding error. NeurEx is obtained from an app-based documentation of the neurological exam (10). EDSS (1) denotes Expanded Disability Status Scale. SNRS (11) denotes Scripps Neurologic Rating Scale. CombiWISE (4) denotes Combinatorial Weight-Adjusted Disability Score. SDMT (2) denotes Symbol Digit Modalities Test. MSFC (12) denotes Multiple Sclerosis Functional Composite. 9HPT denotes 9-Hole Peg Test. 25FW denotes 25-Foot Walk Test. PASAT denotes Paced Auditory Serial Addition Test. Only demographics for patients with valid clinical scores at the first test sitting were summarized in this table (thus, N = 93 instead of N = 112), as patients could only be used in computing correlations if these clinical scores were available.
MS patients without valid clinical scores were excluded from the tabulation. Cross-sectional cohort includes one additional patient with unknown MS subtype not summarized in table.
Descriptive statistics were calculated by excluding missing data.